Trial reportBlood2018
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
2 registry-linked trialsAbstract readClinical Trial, Phase IILetterMulticenter Study
In one paragraph
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial
NCT06536413 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation
Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) With Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib
Who cites it
28 citing papers in PubMed.
- Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).Blood cancer journal · 2019Trial
- Trial
- Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL.Cancer cell international · 2025Article
- [Progress in metabolomics of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Nelfinavir triggers ferroptosis by inducing ER stress mediated downregulation of GPX4/GSH system, upregulation of NRF2/HO-1 axis, and mitochondrial impairment in hepatocellular carcinoma cells.Cell death discovery · 2025Article
- Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma.Clinical and experimental medicine · 2025Review
- Proteasome inhibition induces DNA methylation alteration by attenuating the synthesis of DNA methyltransferase 1 and 3B in colorectal cancer.Scientific reports · 2025Article
- Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.International journal of molecular sciences · 2024Review
- An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2024Article
- Antiretroviral Drug Repositioning for Glioblastoma.Cancers · 2024Article
- The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.Scientific reports · 2023Article
- Targeting the integrated stress response in hematologic malignancies.Experimental hematology & oncology · 2022Review
- The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.Cell death & disease · 2022Article
- Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.The Journal of biological chemistry · 2022Article
- Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.Blood advances · 2022Article
- Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.Frontiers in oncology · 2022Review
- Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.Cancer research · 2021Article
- The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma.Cancers · 2021Review
- Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.Seminars in cancer biology · 2021Review
- The evolving role and utility of off-label drug use in multiple myeloma.Exploration of targeted anti-tumor therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Christoph DriessenDepartment of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.ORCID 0000-0002-1124-7303
Rouven MüllerDepartment of Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland.
Urban NovakDepartment of Medical Oncology, Inselspital, Universitätsspital Bern, Bern, Switzerland.
Nathan CantoniDivision of Hematology, Kantonsspital Aarau AG, Aarau, Switzerland.
Daniel BetticherDivision of Oncology and Hematology, HFR Fribourg, Fribourg, Switzerland.
Nicolas MachUniversity Hospital Geneva, Geneva, Switzerland.
Axel RüferDivision of Hematology, Luzerner Kantonsspital, Lucerne, Switzerland.
Ulrich MeyKantonsspital Graubünden, Chur, Switzerland.
Panagiotis SamarasUniversitaetsspital Zurich, Zurich, Switzerland.
Karin RibiCoordinating Center, International Breast Cancer Study Group, Bern, Switzerland.
Lenka BesseDepartment of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Andrej BesseDepartment of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Catherine BersetCoordinating Center, Swiss Group for Clinical Cancer Research, Bern, Switzerland; and.
Stephanie RondeauCoordinating Center, Swiss Group for Clinical Cancer Research, Bern, Switzerland; and.
Hanne HawleCoordinating Center, Swiss Group for Clinical Cancer Research, Bern, Switzerland; and.
Felicitas HitzDepartment of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Thomas PabstDepartment of Medical Oncology, Inselspital, Universitätsspital Bern, Bern, Switzerland.
Thilo ZanderDepartment of Medical Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.ORCID 0000-0003-3691-7497
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneFemaleHIV Protease InhibitorsHumansMaleMiddle AgedMultiple MyelomaNelfinavirProteasome InhibitorsTreatment OutcomeAntineoplastic AgentsBortezomibDexamethasoneHIV Protease InhibitorsNelfinavirProteasome Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02188537ClinicalTrials.gov
NCT06536413ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.